Brief: Biofrontera Inc Announces FDA Filing Of Supplemental New Drug Application For Ameluz To Permit Up To Three Tubes Per Use
05/02/2024 23:06
Feb 5 (Reuters) - Biofrontera Inc BFRI.O :
* BIOFRONTERA INC - ANNOUNCES FDA FILING OF SUPPLEMENTAL NEW
DRUG
APPLICATION FOR AMELUZ((REG))TO PERMIT UP TO THREE TUBES PER USE
* BIOFRONTERA INC - FDA HAS SET A TARGET ACTION DATE OF
OCTOBER 4,
2024
Source text for Eikon: [https://bitly.ws/3ctp4]
Further company coverage: BFRI.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Biofrontera
See all newsBrief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales